ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth

Niagen Bioscience, Inc.

2024-Q1 EPS reported -$0.01 revenue$22,153,000

Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).
Net loss $0.5M ($0.01 loss per share), improved from $1.9M loss in Q1 2023.
Adjusted EBITDA positive $0.7M vs -$0.1M prior year; cash $27.6M, no debt.
Full-year 2024 outlook reiterated: net sales growth of at least 16%.
Tru Niagen expanded to 700 Vitamin Shoppe stores and 400 Sprouts Farmers Market locations.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Niagen Bioscience, Inc. reported first quarter of 2024 results: revenue $22.2 million, net income $0.5 million, EPS $(0.01) per share. Guidance reaffirmed.

Period: first quarter of 2024
Revenue: $22.2 million
Net income: $0.5 million
EPS: $(0.01) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-021648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.